KOSDAQFinance900120

CXI Healthcare Technology Group

₩2,775▼ 1.07%2026-11-18 close
Market Cap
₩31.5B
Turnover
₩1,918,551
Volume
684 shares
Shares out.
11.3M
PER
4.2×
PBR
0.1×
EPS
₩699
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Prices as of the 2026-11-18 close

01

Report overview

Revenue Down, Q2 Back in the Black as AI Stake Deal Advances

CXI Healthcare Technology Group's revenue and operating profit have declined since the fiscal year ended June 2025, but operating profit turned positive in Q2 2026, and in October 2026 the company agreed to acquire control of an enterprise AI company.

  1. 1

    Revenue for the fiscal year ended June 2026 was KRW 48.6 billion, down 19.7% year on year, and the 6.0% operating margin is the lowest in the disclosed period.

  2. 2

    Q2 2026 operating profit of KRW 4.15 billion followed operating losses in Q4 2025 and Q1 2026, though it was 47.7% lower than a year earlier.

  3. 3

    As of June 2026 the debt ratio was 0.5% and total equity stood at KRW 550.4 billion, indicating a light debt burden.

  4. 4

    The October 2026 decision to take a 55% stake and management control of AIDT Technologies Limited adds AI to the business mix.

  5. 5

    A third-party allotment rights issue decided in February 2026 and reliance on the main subsidiary Yongshenghuoli are the next items to monitor.

02

Business structure

CXI Healthcare Technology Group was set up in 2009 as a holding company in the Cayman Islands and listed on KOSDAQ in 2010. The company reports in Chinese yuan (CNY), and the won amounts in this report are KRW translations.

Its consolidated subsidiaries include Yongshenghuoli, a major Fujian-based subsidiary, CKH Health Industry, which runs the cosmetics business, and other subsidiaries based in Zhejiang and Shanghai.

In health functional foods, the company pursues quality gains and cost reductions by distributing raw materials itself, and it is researching general food formats to diversify products.

It is strengthening online distribution using e-commerce and digital marketing capabilities, and it is also pursuing growth in cosmetics. In October 2026 the company decided to acquire a 55% stake and management control of enterprise AI company AIDT Technologies Limited for USD 45.37 million (about KRW 60.6 billion).

The company described this as a move to add AI as a new growth axis and change the structure of consolidated results.

Subsidiary Yongshenghuoli signed a hospital AI diagnostic system technical support contract worth 33.79 million yuan (about KRW 7.3 billion), which the company said equals about 10% of consolidated revenue.

The business is organized around health functional foods, cosmetics, and AI diagnostics and enterprise AI, and the AI diagnostic counterparties are hospitals.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩20.3B₩7.9B39.2%
2025Q3₩17.1B₩5.1B29.6%
2025Q4₩7.5B-₩3.8B−50.0%
2026Q1₩7.5B-₩2.5B−33.3%
2026Q2₩16.3B₩4.2B25.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023.06₩76.7B₩7.6B₩8.1B10.0%1.7%0.9%
2024.06₩76.7B₩20.8B₩32.4B27.2%6.3%0.6%
2025.06₩60.5B₩10.2B₩13.4B16.9%2.5%0.5%
2026.06₩48.6B₩2.9B₩7.9B6.0%1.4%0.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-10

04

Earnings analysis

Annual revenue was KRW 76.7 billion in both the fiscal years ended June 2023 and June 2024, the highest in the period, then fell to KRW 60.5 billion in the year ended June 2025 (down 21.2%) and KRW 48.6 billion in the year ended June 2026 (down 19.7%), a two-year decline.

Operating profit peaked at KRW 20.8 billion in the year ended June 2024 (up 172.7%) and then fell to KRW 10.2 billion (down 51.0%) and KRW 2.93 billion (down 71.3%), again a two-year decline.

The operating margin rose from 10.0% in the year ended June 2023 to 27.2% in June 2024, then dropped to 16.9% and 6.0% in the two following years, so margins fell along with revenue.

Profit attributable to owners of the parent peaked at KRW 32.4 billion in the year ended June 2024 and then fell to KRW 13.4 billion and KRW 7.92 billion, and net profit including non-controlling interests was reported at the same amounts in each year.

The annual disclosure for the year ended June 2026 cited the decline in revenue and profit at its main subsidiary Yongshenghuoli as the main cause. Operating cash flow was KRW 35.5 billion, KRW 46.7 billion, KRW 43.3 billion and KRW 34.7 billion across the four fiscal years, a smaller decline than operating profit.

Quarterly revenue fell from KRW 20.3 billion in Q2 2025 to KRW 17.1 billion in Q3 and KRW 7.55 billion in Q4, then was KRW 7.54 billion in Q1 2026 and recovered to KRW 16.3 billion in Q2 2026 (KRW translations).

Operating profit of KRW 7.94 billion in Q2 2025 and KRW 5.07 billion in Q3 became an operating loss of KRW 3.78 billion in Q4 2025 and KRW 2.51 billion in Q1 2026, before turning to operating profit of KRW 4.15 billion in Q2 2026.

Profit attributable to owners of the parent in Q2 2026 was KRW 9.51 billion, larger than operating profit, so the non-operating items behind that gap are a point to check in the next periodic report. Profit attributable to owners of the parent over the latest four quarters totals KRW 7.92 billion.

As of June 2026, total equity was KRW 550.4 billion, all of it attributable to owners of the parent, and total liabilities were KRW 2.85 billion.

05

Industry analysis

In health functional foods and cosmetics, competitiveness depends on raw material quality control and the efficiency of online sales channels, and CXI points to its own raw material distribution and e-commerce and digital marketing as its strengths.

Still, revenue has declined since the year ended June 2025, so the results of the channel strategy have not yet shown up as sales growth. Under the domestic listing classification the company appears as KOSDAQ unclassified, while under the WI26 industry classification it falls within health care.

Because China is the core market, local regulation and the translation effect of the yuan both shape how the results should be read. The enterprise AI and AI diagnostics markets serve hospitals and companies, so their demand structure differs from the health food business.

The roughly KRW 60.6 billion purchase price for AIDT equals about 11% of total equity of KRW 550.4 billion as of June 2026. If AI widens the business mix, capital allocation and integration capability will become points to monitor.

Direct numerical comparison with other listed companies in the same sector has limited meaning given the difference in business models, so a comparison built around business structure is more appropriate.

06

Outlook

The starting point for the outlook is the acquisition of control of AIDT decided in October 2026. The company has said it plans to consolidate AIDT and change the structure of its consolidated results.

The timing of closing and the scale of AIDT's contribution after consolidation will need to be checked in later disclosures.

The hospital AI diagnostic system contract (33.79 million yuan, about KRW 7.3 billion) was signed by Yongshenghuoli as a technical support service contract, and when and how much of it will be reflected in consolidated results is the point to verify.

At the annual general meeting disclosed on October 28, 2026, all 11 agenda items passed, including approval of financial statements, re-election of an inside director and auditor, and the liquidation of a subsidiary.

The independent auditor gave an unqualified opinion on the consolidated financial statements for the year ended June 2026. In February 2026 the company decided a third-party allotment rights issue at KRW 515 per new share and said the proceeds would go to working capital including R&D, personnel and marketing costs.

Going forward, completion of the AI consolidation, a recovery in subsidiary results, and how the raised funds are used will together shape the picture. The next periodic report is the Q3 2026 quarterly report covering July to September, with a filing deadline of November 14, 2026.

07

Valuation

PER
4.2×
PBR
0.1×
ROE
1.4%
EPS
₩699
BPS
₩48,563
Dividend per share
—

The price-to-book ratio sits well below 1x, so the share price is low relative to net assets. Market capitalization is also far below total equity as of June 2026. The multiple of price to earnings, measured on profit attributable to owners of the parent over the latest four quarters, is also in a low range.

No cash dividend is recorded in the years where dividend history is shown, so shareholder returns through dividends have not appeared to date. The low multiple relative to net assets can be read together with the fall in earnings, the quarterly swings in profit, and the large size of equity relative to earnings.

How the use of capital and the earnings contribution from AI are reflected will be the key to any change in the multiple. Whether subsidiary results recover and how the earnings structure changes after the AIDT consolidation are the same kind of items to follow.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-10

08

Bull factors

Very low leverage

The debt ratio was 0.5% as of June 2026, with total liabilities of KRW 2.85 billion. All KRW 550.4 billion of equity is attributable to owners of the parent, so reliance on outside borrowing is low.

Operating cash flow was still KRW 34.7 billion for the year ended June 2026, showing cash generation held up during the earnings decline.

Return to operating profit in Q2 2026

After operating losses in Q4 2025 and Q1 2026, operating profit returned to KRW 4.15 billion in Q2 2026. Profit attributable to owners of the parent also turned positive at KRW 9.51 billion. Quarterly revenue rose from KRW 7.54 billion in Q1 2026 to KRW 16.3 billion in Q2 2026 (KRW translations).

AI expansion and a hospital contract

In October 2026 the company decided to take a 55% stake and management control of AIDT Technologies Limited and presented AI as a new growth axis.

Subsidiary Yongshenghuoli signed a hospital AI diagnostic technical support contract worth about KRW 7.3 billion, which the company said equals about 10% of consolidated revenue. If the business base widens, the structure of consolidated results could change.

09

Bear factors

Two straight years of declines

Revenue fell to KRW 60.5 billion in the year ended June 2025 and KRW 48.6 billion in the year ended June 2026, a two-year decline. Operating profit fell from KRW 20.8 billion in the year ended June 2024 to KRW 2.93 billion in the year ended June 2026, and the operating margin dropped from 27.2% to 6.0%. The earnings base has shrunk considerably.

Dependence on one subsidiary

The annual disclosure for the year ended June 2026 cited the decline in revenue and profit at subsidiary Yongshenghuoli as the main cause of the consolidated drop. Consolidated results are therefore heavily tied to a single subsidiary. If Yongshenghuoli does not recover, a rebound in consolidated profit could be limited.

Quarterly losses and smaller operating cash flow

The company posted operating losses of KRW 3.78 billion in Q4 2025 and KRW 2.51 billion in Q1 2026, two consecutive loss quarters. Operating cash flow declined from KRW 43.3 billion in the year ended June 2025 to KRW 34.7 billion in the year ended June 2026.

The return to operating profit in Q2 2026 is a single quarter, so further quarters are needed to establish a trend.

10

Risk factors

Concentration and China operating environment

The financial statements are prepared in Chinese yuan, and the main operations run through subsidiaries in China. Local regulatory changes and the yuan exchange rate can change KRW-translated results. Because swings at Yongshenghuoli feed directly into consolidated results, that concentration is itself a risk.

Execution and integration of the AI acquisition

The purchase price for control of AIDT is USD 45.37 million (about KRW 60.6 billion), roughly 11% of total equity as of June 2026. Because the target operates a different business from the core operations, the timing of management integration and of any earnings contribution is uncertain.

Consolidated results will not reflect the deal until closing, and the contribution after closing will have to be confirmed through disclosures.

Capital raising and subsidiary restructuring

In February 2026 the company decided a third-party allotment rights issue at KRW 515 per new share. New share issuance can dilute the value held by existing shareholders.

A subsidiary liquidation item also passed at the October 2026 general meeting, so the scope and direction of business restructuring need to be followed together.

11

What to watch next

  1. November 14, 2026

    This is the filing deadline for the Q3 2026 quarterly report covering July to September. It is the point to check whether the operating margin holds at the Q2 level, whether Yongshenghuoli's results recover quarter on quarter, and what non-operating items explain the gap between operating profit and profit attributable to owners.

  2. Date to be disclosed (TBD)

    This is the point to confirm whether and when the AIDT control acquisition closes, the scope of consolidation, and how the purchase is funded. How AI revenue and profit are recorded in consolidated results after closing is the next item to verify.

  3. February 14, 2027

    This is the filing deadline for the half-year report covering July to December 2026. It is the point to check the first-half revenue trend, how much of the hospital AI diagnostic contract appears in consolidated revenue, and the direction of cash flow.

  4. May 15, 2027

    This is the filing deadline for the Q1 2027 quarterly report covering January to March. It is the point to check whether the operating margin, which was 6.0% for the year ended June 2026, improves in the first quarter after the AI consolidation and whether subsidiary results recover.

12

Overall view

CXI's revenue and operating profit have declined since the year ended June 2025, reaching KRW 48.6 billion and KRW 2.93 billion in the year ended June 2026. The operating margin fell to 6.0%, and profit attributable to owners of the parent dropped to KRW 7.92 billion.

On the other side, operating profit returned to KRW 4.15 billion in Q2 2026, and a debt ratio of 0.5% with total equity of KRW 550.4 billion supports financial stability.

The October 2026 decision to acquire control of AIDT could change the business structure, but closing and its earnings contribution have not yet been confirmed. Reliance on subsidiary Yongshenghuoli, the February 2026 rights issue, and two consecutive quarters of operating losses remain the main negatives.

The price-to-book ratio sits well below 1x, and how quickly earnings recover is the point on which views differ. The next items to check are the operating margin in the Q3 2026 quarterly report and the disclosures on the AIDT consolidation.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. k5.co.kr
  3. digitaltoday.co.kr
  4. m.sedaily.com
  5. digitaltoday.co.kr
  6. sedaily.com
  7. ckhfnh.co.kr
  8. investing.com
  9. news.nate.com
  10. comp.wisereport.co.kr
  11. tradingkey.com
  12. file.alphasquare.co.kr
  13. specialtimes.co.kr
  14. specialtimes.co.kr
  15. kr.investing.com
  16. judal.co.kr
  17. kr.investing.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis